2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Cardiac Contractility Modulation in Drug-Resistant Heart Failure
This video features a candid discussion between Dr. William Abraham and Prof. Andrew Coats following the recent publication of the 2021 ESC Guidelines for Heart Failure. The physicians discuss cardiac contractility modulation therapy and deliberate over appropriate timing for interventional device-based therapies for patients who remain symptomatic despite GDMT. Both doctors also share their viewpoints on patients’ quality versus quantity of life and how that balance affects their decisions and overall treatment strategies. The video also features a presentation on cardiac contractility modulation in drug-resistant heart failure given by Prof. Coats at the 2021 ESC Heart Failure Congress.
- October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Comments 0
Login to view comments.
Click here to Login
